VRTX250110C470000
- 0.60
- 0.000.00%
Vertex Pharmaceuticals Newsroom
Vertex Pharmaceuticals Analyst Ratings
Morgan Stanley Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Cuts Target Price to $456
Wells Fargo Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Cuts Target Price to $460
Wells Fargo Issues a Buy Rating on Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals: Hold Rating Amid Mixed Results for Suzetrigine in LSR and Optimistic Prospects in Acute Pain
RBC Lifts Price Target on Vertex Pharmaceuticals to $401 From $400, Keeps Sector Perform Rating
Bernstein Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $441
Analysts Are Bullish on Top Healthcare Stocks: Oruka Therapeutics (ORKA), Vertex Pharmaceuticals (VRTX)
Truist Financial Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $460
Truist has lowered the Vertex Target Price to 460 dollars.
A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $430 to $525
RBC Capital Keeps Their Hold Rating on Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities
TD Cowen Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan
Barclays Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $418
Analysts Conflicted on These Healthcare Names: Neurocrine (NBIX), Vertex Pharmaceuticals (VRTX) and Jasper Therapeutics (JSPR)
J.P. Morgan Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Cuts Target Price to $500
JPMorgan Adjusts Price Target on Vertex Pharmaceuticals to $500 From $503, Keeps Overweight Rating
Scotiabank Adjusts Price Target on Vertex Pharmaceuticals to $430 From $426, Keeps Sector Perform Rating